Alexandria® — the world’s largest body of medical evidence for clinical decision support and LLM training.

Read the release
Learn more
Logo
  • Solutions
        • Health Systems
          • Pharmacy
          • Research Informatics
          • Value Based Care / Quality
          • GME
        • Life Sciences
          • Precision Medicine AI/ML
          • HEOR, Medical Affairs & RWE
          • Research & Development
          • Commercial Analytics
  • Technology
        • Content
          • Alexandria®
        • Automation Solutions
          • Atropos Evidence™ Agent
          • ChatRWD®
          • Green Button®
          • Forge®
        • Data
          • GENEVA OS®
          • Atropos Evidence™ Network
          • Data Quality Scoring
  • About
    • About Us
    • Careers
  • Resources
    • Resource Center
    • Publications
    • Customer Stories
    • News & Media
    • Press Releases
    • Blog
  • Contact Us
  • Login
ChatRWD™ beta Exceeds Big Tech LLMs on Physician Trust and Ability to Answer Questions Completely with High-Quality Evidence: New Study Released

ChatRWD™ beta Exceeds Big Tech LLMs on Physician Trust and Ability to Answer Questions Completely with High-Quality Evidence: New Study Released

by a9b1da23_admin | Jul 2, 2024 | Press Release, White Paper

The Research and Results are Published in Preprint on arXiv, Continuing the Company’s Commitment to Provide Transparency on its Methodology Read the full press release here PALO ALTO, Calif.—July 2, 2024— Today, Atropos Health, a pioneer in translating real-world...
Atropos Evidence™ Network: Over 300 Million Patients – now the Industry’s Largest Federated Healthcare Data Network

Atropos Evidence™ Network: Over 300 Million Patients – now the Industry’s Largest Federated Healthcare Data Network

by a9b1da23_admin | Jun 24, 2024 | Press Release

New partners – Forian and Syndesis Health join the Atropos Evidence Network and new customer Translational Drug Development (TD2) gains immediate access to clinical insights generated from Atropos Health’s new data contributors. Read the full press release...
GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes

GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes

by Julia Rudo | Jun 14, 2024 | Publications

An abstract titled, “GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes,” was published in Diabetes, a publication from the American Diabetes Association, and subsequently presented by authors Faidat A. Ishola, C. William Pike, and Sun H. Kim. Dr. Pike...
Forbes: Atropos Health helps doctors, pharma companies and insurers figure out how patients react to treatments in the real-world

Forbes: Atropos Health helps doctors, pharma companies and insurers figure out how patients react to treatments in the real-world

by a9b1da23_admin | May 23, 2024 | News and Media

Katie Jennings of Forbes sat down with Dr. Brigham Hyde, CEO and co-Founder of Atropos Health to discuss the $33M Series B fundraise.See the full article here:...
GLP-1 Agonists Can Prevent Liver Disease Progression in Patients with Metabolic and Alcohol-Associated Liver Disease (METALD)

GLP-1 Agonists Can Prevent Liver Disease Progression in Patients with Metabolic and Alcohol-Associated Liver Disease (METALD)

by Julia Rudo | May 20, 2024 | Publications

An abstract titled, “GLP-1 Agonists Can Prevent Liver Disease Progression in Patients with Metabolic and Alcohol-Associated Liver Disease (MetALD),” was published in Digestive Disease Week and subsequently presented by authors Amir Gougol, C. William Pike, Niloufar...
« Older Entries
Next Entries »
DiviWP Logo
  • Follow
  • Follow

Solutions

Health Systems

Pharmacy

Research Informatics

Value Based Care / Quality

GME

Life Sciences

Precision Medicine AI/ML

HEOR, Medical Affairs & RWE

Research & Development

Commercial Analytics

Technology

Content

Alexandria®

Automation Solutions

Atropos Evidence™ Agent

ChatRWD®

Green Button®

Forge®

Data

GENEVA OS®

Atropos Evidence™ Network

Data Quality Scoring

About

  • About Us
  • Careers

Resources

  • Resources Center
  • Publications
  • Customer Stories
  • News & Media
  • Press Releases
  • Blog

Copyright © 2026 Atropos Health. All Rights Reserved | Privacy Policy | Ethics Report | Terms of Service

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}